Publications

Article

Policies to Influence Perceptions about COVID-19 Risk: The Case of Maps

By: Claudia Engel, Jonathan Rodden and Marco Tabellini

Choropleth disease maps have become an important tool for informing the public about the risks posed by COVID-19. In a survey conducted in the U.S. state of Georgia in June 2020, we randomly assigned respondents to view either of two maps. The first one reported... View Details

Keywords: Disease Surveillance; Health Pandemics; Risk and Uncertainty; Perception; Policy

31 May 2016
First Look

May 31, 2016

June 2016 Medical Care Vaccination Rates Are Associated with Functional Proximity but Not Base Proximity of Vaccination Clinics By: Beshears, John, James J. Choi, David Laibson, Brigitte C. Madrian, and... View Details

Keywords: Sean Silverthorne

Article

Sustainability, Business, and Health

By: George Serafeim, Amanda M. Rischbieth and Howard K. Koh

The coronavirus disease 2019 (COVID-19) pandemic has demonstrated that response demands involvement from every sector of society. As a major example, some businesses have stepped up in ways previously unimaginable. Garment companies have repurposed production to face... View Details

Keywords: COVID; COVID-19; Sustainability; Health And Wellness; Corporate Social Responsibility; Health Pandemics; Health; Corporate Social Responsibility and Impact; Corporate Accountability; Health Care and Treatment

Find at Harvard

January 2017 (Revised October 2018)
Case

Novartis: A Transformative Deal

By: David Collis and Ashley Hartman

When Joe Jimenez became CEO of Swiss-based Novartis in 2010, replacing longtime CEO Dan Vasella, he assumed control of one of the top pharmaceutical companies in the world. Vasella, an avowed advocate of diversification, had expanded the scope of the company and... View Details

Keywords: Novartis; GlaxoSmithKline; Asset Swap; Acquisitions; Divestiture; Strategy Alignment; Pharmaceuticals; Strategy; Business Strategy; Corporate Strategy; Diversification; Consolidation; Mergers and Acquisitions; Pharmaceutical Industry

May 2025 (Revised June 2025)
Supplement

Michael Ku and Global Clinical Supply at Pfizer Inc.: Bringing Hope to Patients (D)

By: Linda A. Hill and Lydia Begag

This fourth installment in the Pfizer Global Clinical Supply (GCS) transformation case series highlights how over a decade of cultural and digital evolution positioned GCS to meet unprecedented global challenges. In 2011, Michael Ku became the Vice President of GCS and... View Details

February 2021 (Revised May 2021)
Case

SafeGraph: Selling Data as a Service

By: Ramana Nanda, Abhishek Nagaraj and Allison Ciechanover

Set in January 2021, the CEO of SafeGraph, a four-year-old startup that sold Data as a Service, looked to the future. His aim was to become the most trusted source for data about a physical place. The company provided points of interest (POI) and foot traffic data on... View Details

Keywords: Data As A Service; Monetization; Pricing; Business Startups; Analytics and Data Science; Consumer Behavior; Analysis; Business Model; Health Pandemics; Information Industry; United States

June 2021
Article

From Predictions to Prescriptions: A Data-driven Response to COVID-19

By: Dimitris Bertsimas, Léonard Boussioux, Ryan Cory-Wright, Arthur Delarue, Vassilis Digalakis Jr, Alexander Jacquillat, Driss Lahlou Kitane, Galit Lukin, Michael Lingzhi Li, Luca Mingardi, Omid Nohadani, Agni Orfanoudaki, Theodore Papalexopoulos, Ivan Paskov, Jean Pauphilet, Omar Skali Lami, Bartolomeo Stellato, Hamza Tazi Bouardi, Kimberly Villalobos Carballo, Holly Wiberg and Cynthia Zeng

The COVID-19 pandemic has created unprecedented challenges worldwide. Strained healthcare providers make difficult decisions on patient triage, treatment and care management on a daily basis. Policy makers have imposed social distancing measures to slow the disease, at... View Details

Keywords: COVID-19; Health Pandemics; AI and Machine Learning; Forecasting and Prediction; Analytics and Data Science

September 2022
Case

Deciding When to Engage on Societal Issues

By: Hubert Joly and Amram Migdal

This case provides brief descriptions of 18 examples of corporate leaders confronting questions of whether and how to engage with societal issues, including social, political, and environmental issues. Social issues include COVID-19; social and racial justice;... View Details

Keywords: Political Issues; Social Justice; Racial Justice; Environmental Issues; Social Issues; Corporate Social Responsibility and Impact; Values and Beliefs

April 2024 (Revised November 2024)
Case

Moderna: Pioneering a People Platform to Accelerate Science Innovation

By: Tatiana Sandino, Emil Dy and Samuel Grad

Moderna was founded in 2010 to explore how messenger ribonucleic acid (mRNA) could be used to create breakthrough medicines by encoding instructions for the body to create antibodies. When Stéphane Bancel (HBS 2000) took over in 2011, he bet on the potential of this... View Details

Keywords: Disruptive Innovation; Talent and Talent Management; Selection and Staffing; AI and Machine Learning; Digital Strategy; Innovation and Management; Leadership Development; Management Practices and Processes; Management Systems; Organizational Culture; Performance Evaluation; Alignment; Employee Relationship Management; Science-Based Business; Expansion; Pharmaceutical Industry; Biotechnology Industry; United States

January–February 2023
Article

Forecasting COVID-19 and Analyzing the Effect of Government Interventions

By: Michael Lingzhi Li, Hamza Tazi Bouardi, Omar Skali Lami, Thomas Trikalinos, Nikolaos Trichakis and Dimitris Bertsimas

We developed DELPHI, a novel epidemiological model for predicting detected cases and deaths in the prevaccination era of the COVID-19 pandemic. The model allows for underdetection of infections and effects of government interventions. We have applied DELPHI across more... View Details

Keywords: COVID-19 Pandemic; Epidemics; Analytics and Data Science; Health Pandemics; AI and Machine Learning; Forecasting and Prediction

January 2009
Case

When Supply is of Public Interest: Roche & Tamiflu

The case focuses on the challenges of Roche maintaining a supply network for a global influenza pandemic response initiative based on its antiviral drug Tamiflu. The Roche group is a 40 billion CHF company consisting of a pharmaceutical division and a diagnostic... View Details

Keywords: Global Strategy; Health Pandemics; Distribution; Logistics; Production; Supply Chain Management; Performance Capacity; Pharmaceutical Industry